Mariko Eguchi
Profesor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Introduction DUX4 is rearranged and overexpressed in a subgroup of acute lymphoblastic leukemia (ALL) with B‐precursor phenotype, with a favorable outcome. Even though characteristic gene expression signature as well as surface expression of CD2/CD371 could be a hallmark of DUX4 ‐rearranged ALL, actual detection of DUX4 rearrangement is, however, largely dependent on whole transcriptome analysis due to the highly repetitive nature of DUX4 gene loci and insertion as the main mechanism of fusion gene formation. Methods Polymerase chain reactions (PCRs) with several combinations of multiplex primers located on DUX4 and IGH gene loci were used for the detection of DUX4::IGH , which represents more than 90% of DUX4 fusion. Results DUX4::IGH fusion was successfully detected in three out of 50 ALL cases analyzed by standard PCR, and these positive cases showed variable insertion of DUX4 into the IGH locus. In all patients, sequences of unknown origin were observed at the junction of DUX4 and IGH sequences, indicating the role of the V(D)J recombination mechanism in fusion gene formation. Although DUX4 is tandemly repeated at its locus, only a single copy of the DUX4 sequence was detected at the IGH locus in two of the three DUX4 ‐rearranged ALL cases. As previously reported, both CD2 and CD371 were positive in all cases with DUX4 :: IGH fusion, suggesting that the combination of CD2 and CD371 could be a more reliable marker for detecting the presence of this fusion. Conclusions Identification of DUX4 :: IGH fusion in ALL could be possible more easily by a simple multiplex PCR strategy.
Year:
2025
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.
Year:
2024
Year:
2022
Collaborators (30)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
Martin Schrappe
-
riccardo masetti
Assistant Professor
University of Bologna
Kjeld Schmiegelow
-
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Atsushi Manabe
Professor
Hokkaido University
Gabriele Escherich
-
Valentino Conter
-
John Choi
The University of Alabama
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Kathryn Roberts
St. Jude Children's Research Hospital
David Teachey
Professor
Children's Hospital of Philadelphia
Daisuke Tomizawa
Head
National Center For Child Health and Development
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Motohiro Kato
-
Takao Deguchi
Head of Division
National Center For Child Health and Development
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Masatoshi Takagi
Tokyo Medical and Dental University
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Make your next move.
Prepare your application
Review drafts before you send them.